Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
B-cell maturation antigen-directed bispecific antibodies in plasmablastic lymphoma.
Hofer KD, Wolfensberger N, Bachofner A, Schneidawind C, Stühler C, Bühler MM, Abela IA, Müller NJ, Zenz T, Manz MG, Rösler W, Khanna N, Schneidawind D. Hofer KD, et al. Among authors: schneidawind c. Br J Haematol. 2024 Aug;205(2):722-725. doi: 10.1111/bjh.19571. Epub 2024 May 23. Br J Haematol. 2024. PMID: 38782604 No abstract available.
Treatment response of advanced HNSCC towards immune checkpoint inhibition is associated with an activated effector memory T cell phenotype.
Schumacher M, Beer S, Moraes Ribeiro E, Korkmaz F, Keppeler H, Fitzel R, Erkner E, Radszuweit P, Lengerke C, Schneidawind C, Hoefert S, Mauz PS, Schneidawind D. Schumacher M, et al. Among authors: schneidawind c. Front Oncol. 2024 Mar 7;14:1333640. doi: 10.3389/fonc.2024.1333640. eCollection 2024. Front Oncol. 2024. PMID: 38515578 Free PMC article.
PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivity.
Moraes Ribeiro E, Secker KA, Nitulescu AM, Schairer R, Keppeler H, Wesle A, Schmid H, Schmitt A, Neuber B, Chmiest D, Podavini S, Märklin M, Klimovich B, Schmitt M, Korkmaz F, Lengerke C, Schneidawind C, Schneidawind D. Moraes Ribeiro E, et al. Among authors: schneidawind c. J Immunother Cancer. 2024 Jan 31;12(1):e007829. doi: 10.1136/jitc-2023-007829. J Immunother Cancer. 2024. PMID: 38296597 Free PMC article.
The RORɣ/SREBP2 pathway is a master regulator of cholesterol metabolism and serves as potential therapeutic target in t(4;11) leukemia.
Erkner E, Hentrich T, Schairer R, Fitzel R, Secker-Grob KA, Jeong J, Keppeler H, Korkmaz F, Schulze-Hentrich JM, Lengerke C, Schneidawind D, Schneidawind C. Erkner E, et al. Among authors: schneidawind c. Oncogene. 2024 Jan;43(4):281-293. doi: 10.1038/s41388-023-02903-3. Epub 2023 Nov 29. Oncogene. 2024. PMID: 38030791 Free PMC article.
Targeting MYC in combination with epigenetic regulators induces synergistic anti-leukemic effects in MLLr leukemia and simultaneously improves immunity.
Fitzel R, Secker-Grob KA, Keppeler H, Korkmaz F, Schairer R, Erkner E, Schneidawind D, Lengerke C, Hentrich T, Schulze-Hentrich JM, Schneidawind C. Fitzel R, et al. Among authors: schneidawind c. Neoplasia. 2023 Jul;41:100902. doi: 10.1016/j.neo.2023.100902. Epub 2023 May 4. Neoplasia. 2023. PMID: 37148657 Free PMC article.
Low Graft Invariant Natural Killer T-Cell Dose Is a Risk Factor for Cytomegalovirus Reactivation After Allogeneic Hematopoietic Cell Transplantation.
Schneidawind D, Duerr-Stoerzer S, Liewer S, Renner S, Sánchez Navarro B, Atar D, Keppeler H, Beck R, Hamprecht K, Kanz L, Lengerke C, Schneidawind C. Schneidawind D, et al. Among authors: schneidawind c. Transplant Cell Ther. 2022 Aug;28(8):513.e1-513.e4. doi: 10.1016/j.jtct.2022.05.011. Epub 2022 May 14. Transplant Cell Ther. 2022. PMID: 35580734 Free article.
23 results